Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adenomatous polyps

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Adenomatous polyps. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-001886-40 Sponsor Protocol Number: G2M-777 SYS 01/2004 Start Date*: 2006-06-06
    Sponsor Name:TopoTarget Germany AG
    Full Title: A randomized, double-blind, placebo-controlled parallel group study to assess the safety and efficacy of a new oral formulation of 2-propyl pentanoic acid (2-PPA, PEAC minitablets) for the treatmen...
    Medical condition: Familial adenomatous polyposis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10059327 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002836-18 Sponsor Protocol Number: EPA/POL/03 Start Date*: 2006-10-09
    Sponsor Name:S.L.A. Pharma (UK) Ltd
    Full Title: A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid.
    Medical condition: Familial adenomatous polyposis (FAP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059327 Familial adenomatous polyposis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002809-34 Sponsor Protocol Number: EPA-POL-04 Start Date*: 2018-08-16
    Sponsor Name:SLA Pharma (UK) Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP)
    Medical condition: Familial Adenomatous Polyposis (FAP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10059327 Familial adenomatous polyposis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) NL (Completed) DE (Ongoing) IT (Prematurely Ended) DK (Completed) PL (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005527-12 Sponsor Protocol Number: 55868 Start Date*: 2016-12-02
    Sponsor Name:
    Full Title: Sirolimus for the treatment of severe intestinal polyposis in patients with familial adenomatous polyposis (FAP); a pilot study
    Medical condition: Familial adenomatous polyposis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001084-27 Sponsor Protocol Number: APAC Start Date*: 2006-06-16
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Phase I/II study of prevention of Colorectal Cancer CRC with Allopurinol in High-Risk Subjects
    Medical condition: CHEMOPREVENTION OF COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048832 Colon adenoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002228-40 Sponsor Protocol Number: A3191193 Start Date*: 2006-08-28
    Sponsor Name:PFIZER
    Full Title: A PHASE III PLACEBO-CONTROLLED TRIAL OF CELECOXIB IN GENOTYPE POSITIVE SUBJECTS WITH FAMILIAL ADENOMATOUS POLYPOSIS
    Medical condition: FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Completed) IT (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) BE (Prematurely Ended) DE (Completed) HU (Prematurely Ended) SK (Completed) BG (Not Authorised)
    Trial results: View results
    EudraCT Number: 2011-001815-29 Sponsor Protocol Number: MDL_2011_36557 Start Date*: 2011-11-11
    Sponsor Name:UMC Utrecht
    Full Title: Chemopreventive effects of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas
    Medical condition: sporadic colorectal adenomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069428 Colon adenomatous polyp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000240-30 Sponsor Protocol Number: 80308 Start Date*: 2022-04-19
    Sponsor Name:Center for Experimental and Molecular Medicine, G2 (AMC)
    Full Title: The chemopreventive effect of Lithium on adenoma development in patients with familial adenomatous polyposis (FAP); a pilot study
    Medical condition: Familial adenomatous polyposis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001351-40 Sponsor Protocol Number: MES-CT01 Start Date*: 2012-05-02
    Sponsor Name:SOFAR SPA
    Full Title: ND
    Medical condition: NA
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048832 Colon adenoma PT
    14.1 10017947 - Gastrointestinal disorders 10013549 Diverticulosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005694-23 Sponsor Protocol Number: CB-17-01/05 Start Date*: 2011-12-20
    Sponsor Name:COSMO TECHNOLOGIES LTD
    Full Title: Polyp detection rate after single oral dose of methylene blue MMX(R) modified release tablets administered to subjects undergoing outpatients colonoscopy
    Medical condition: patients scheduled for the screening or surveillance colonoscopy and meeting the joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer and the Ameri...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10014805 Endoscopy PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048832 Colon adenoma PT
    14.1 10017947 - Gastrointestinal disorders 10048646 Polyp colorectal PT
    Population Age: Newborns, Infants and toddlers, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000427-41 Sponsor Protocol Number: CPPFAP-310 Start Date*: 2014-05-15
    Sponsor Name:Cancer Prevention Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X/Sulindac Compared With CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis (FAP)
    Medical condition: Familial Adenomatous Polyposis (FAP)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000131-51 Sponsor Protocol Number: 1921 Start Date*: 2019-03-07
    Sponsor Name:Zealand University Hospital
    Full Title: Preoperative endoscopic treatment with fosfomycin and metronidazole in patients with right-sided colon cancer and colon adenoma: a clinical proof-of-concept intervention study MEFO trial
    Medical condition: Colon cancer in track 1. Colon adenoma in track 2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048832 Colon adenoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003398-28 Sponsor Protocol Number: C0524T17 Start Date*: 2007-11-15
    Sponsor Name:Centocor BV
    Full Title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderat...
    Medical condition: Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) AT (Completed) BE (Completed) FR (Completed) LT (Completed) LV (Completed) NL (Completed) DK (Completed) SE (Completed) BG (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-005256-16 Sponsor Protocol Number: CSPP100A2404 Start Date*: 2008-03-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in p...
    Medical condition: Essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003397-94 Sponsor Protocol Number: C0524T16 Start Date*: 2007-09-05
    Sponsor Name:Centocor BV
    Full Title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderate...
    Medical condition: Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) AT (Prematurely Ended) BE (Completed) FR (Completed) NL (Prematurely Ended) LT (Completed) LV (Prematurely Ended) SE (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003123-38 Sponsor Protocol Number: RPC01-202 Start Date*: 2012-12-11
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY...
    Medical condition: Moderately to severely active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed) GR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004293-33 Sponsor Protocol Number: RPC01-3202 Start Date*: 2018-03-06
    Sponsor Name:Celgene International II Sàrl
    Full Title: Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) LT (Completed) DE (Completed) FR (Completed) SI (Completed) AT (Completed) BG (Completed) GR (Completed) ES (Completed) SE (Completed) NL (Completed) PL (Completed) PT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-004292-31 Sponsor Protocol Number: RPC01-3201 Start Date*: 2018-05-21
    Sponsor Name:Celgene International II Sàrl
    Full Title: Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) DE (Completed) BG (Prematurely Ended) ES (Ongoing) NO (Completed) BE (Completed) DK (Completed) PL (Prematurely Ended) IE (Prematurely Ended) GB (GB - no longer in EU/EEA) HR (Completed) FR (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003084-37 Sponsor Protocol Number: SLU01 Start Date*: 2014-10-15
    Sponsor Name:SOTIO a.s.
    Full Title: A phase I/II study to evaluate safety and efficacy of DCVAC/LuCa added to standard first line chemotherapy with carboplatin and paclitaxel +/- immune enhancers (interferon-α and hydroxychloroquine)...
    Medical condition: Stage IV Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025070 Lung carcinoma cell type unspecified stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003986-33 Sponsor Protocol Number: APD334-302 Start Date*: 2019-07-01
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) FR (Completed) DK (Completed) LT (Completed) BG (Completed) PT (Completed) LV (Prematurely Ended) HU (Completed) PL (Completed) HR (Completed) ES (Ongoing) IT (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 10:58:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA